IRIS

Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma / Loffler, Mw; Gori, S; Izzo, F; Mayer-Mokler, A; Ascierto, P; Konigsrainer, A; Ma, Yt; Sangro, B; Francque, S; Vonghia, L; Inno, A; Avallone, A; Ludwig, J; Alcoba, Dd; Flohr, C; Aslan, K; Mendrzyk, R; Schuster, H; Borrelli, M; Valmori, D; Chaumette, T; Heidenreich, R; Gouttefangeas, C; Forlani, G; Tagliamonte, M; Fusco, C; Penta, R; Inarrairaegui, M; Gnad-Vogt, U; Reinhardt, C; Weinschenk, T; Accolla, Rs; Singh-Jasuja, H; Rammensee, Hg; Buonaguro, L. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 28:12(2022), pp. 2555-2566. [10.1158/1078-0432.CCR-21-4424]

Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma

Ascierto P;
2022
2022
Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma / Loffler, Mw; Gori, S; Izzo, F; Mayer-Mokler, A; Ascierto, P; Konigsrainer, A; Ma, Yt; Sangro, B; Francque, S; Vonghia, L; Inno, A; Avallone, A; Ludwig, J; Alcoba, Dd; Flohr, C; Aslan, K; Mendrzyk, R; Schuster, H; Borrelli, M; Valmori, D; Chaumette, T; Heidenreich, R; Gouttefangeas, C; Forlani, G; Tagliamonte, M; Fusco, C; Penta, R; Inarrairaegui, M; Gnad-Vogt, U; Reinhardt, C; Weinschenk, T; Accolla, Rs; Singh-Jasuja, H; Rammensee, Hg; Buonaguro, L. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 28:12(2022), pp. 2555-2566. [10.1158/1078-0432.CCR-21-4424]
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1014268
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 63
  • ???jsp.display-item.citation.isi??? 64
social impact